Assessment of influence of two regimens of intravenous administration of a klodronat on dynamics of a pain syndrome and quality of life of patients with breast cancer metastasises in skeleton bones
https://doi.org/10.18027/2224-5057-2017-2-28-32
Abstract
Evaluation of the effect of the clodronate therapy on the dynamics of chronic pain syndrome and on the quality of life of patients with breast cancer with metastatic lesions of bones after previous treatment with drug containing zoledronic acid. Topicality: Breast cancer is characterized by tendency to early metastasize: about 6% of patients already at diagnosis have metastatic form of the disease. The most frequent targets are the bones: for the frequency of bone metastasis, breast cancer is on the second place among malignant tumors and for the specific weight on the first place [1, 2, 3, 4]. On the early stages, metastatic bone lesions can be asymptomatic.
About the Authors
V. G. Moskin
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow
Russian Federation
Assistant the Department of Oncology and Thoracic Surgery
Russian Federation
Assistant the Department of Oncology and Thoracic Surgery
L. M. Kogoniya
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow
Russian Federation
Doctor of Medical Sciences, Professor of the Department of Oncology and Thoracic Surgery
Russian Federation
Doctor of Medical Sciences, Professor of the Department of Oncology and Thoracic Surgery
References
1. Ахмедов Б.П. Метастатические опухоли. М.,1984. С. 97–98. [Akhmedov B. P. Metastatic tumors. Moscow, 1984, pp. 97–98. (In Russ.)].
2. Семиглазов В.В., Топузов Э.Э. Рак молочной железы. М.: МЕДпресс-информ, 2009. С. 21–23. [Semiglazov V.V., Topuzov E.E. Breast cancer, Мoscow: MEDpress-inform, 2009, pp. 21–23. (In Russ.)].
3. Elomaa I. Acta Oncol., 2000, Vol. 17, pp. 588–592.
4. Von Minckwitz G., M bus V., Schneeweiss A. F. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer J. Clin. Oncol., 2013, Vol. 31, No. 28, pp. 3531–3539.
5. Kaye J.A., Jick H. Antibiotics and the risk of breast cancer, Epidemiology, 2005, Vol. 16, No. 5, pp. 688–690.
6. Costa L. Which bisphosphonate to treat bone metastases? The Lancet Oncology, 2014, Vol. 15, Issue 1, pp. 15–18.
7. O”Rourke N.P., McCloskey E. V., Kanis J.A. Single intravenous infusion of clodronate in control of metastatic bone pain – A double blind trial, 1993, Vol. 29, Suppl. 6, p. S202.
Review
For citations:
Moskin V.G., Kogoniya L.M. Assessment of influence of two regimens of intravenous administration of a klodronat on dynamics of a pain syndrome and quality of life of patients with breast cancer metastasises in skeleton bones. Malignant tumours. 2017;(2):28-32. (In Russ.) https://doi.org/10.18027/2224-5057-2017-2-28-32
Views:
846
Email this article 